IL133907A0 - Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor - Google Patents

Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Info

Publication number
IL133907A0
IL133907A0 IL13390798A IL13390798A IL133907A0 IL 133907 A0 IL133907 A0 IL 133907A0 IL 13390798 A IL13390798 A IL 13390798A IL 13390798 A IL13390798 A IL 13390798A IL 133907 A0 IL133907 A0 IL 133907A0
Authority
IL
Israel
Prior art keywords
glucocidase
thiazolidinedione
diabetes
inhibitor
alpha
Prior art date
Application number
IL13390798A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of IL133907A0 publication Critical patent/IL133907A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IL13390798A 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor IL133907A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002112 WO1999003478A1 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Publications (1)

Publication Number Publication Date
IL133907A0 true IL133907A0 (en) 2001-04-30

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13390798A IL133907A0 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor

Country Status (27)

Country Link
EP (1) EP1001784A1 (xx)
JP (1) JP2001510160A (xx)
KR (1) KR20010021952A (xx)
CN (1) CN1263467A (xx)
AP (1) AP2000001735A0 (xx)
AR (2) AR016350A1 (xx)
AU (1) AU8449098A (xx)
BG (1) BG104062A (xx)
BR (1) BR9810292A (xx)
CA (1) CA2297133A1 (xx)
CO (1) CO4940489A1 (xx)
DZ (1) DZ2563A1 (xx)
EA (1) EA200000140A1 (xx)
GB (1) GB9715298D0 (xx)
HU (1) HUP0003626A3 (xx)
ID (1) ID23804A (xx)
IL (1) IL133907A0 (xx)
MA (1) MA24608A1 (xx)
NO (1) NO20000230D0 (xx)
OA (1) OA11312A (xx)
PE (1) PE99499A1 (xx)
PL (1) PL338140A1 (xx)
SK (1) SK612000A3 (xx)
TR (1) TR200000133T2 (xx)
UY (1) UY25101A1 (xx)
WO (1) WO1999003478A1 (xx)
ZA (1) ZA986364B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1849475A1 (en) 1999-06-21 2007-10-31 Eli Lilly & Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
DE122008000018I1 (de) * 2000-01-21 2008-08-14 Novartis Pharma Ag Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US20030040490A1 (en) * 2000-02-24 2003-02-27 Yasuo Sugiyama Drugs containing combined active ingredients
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
MXPA03006217A (es) 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
CN1874774B (zh) 2003-10-31 2011-04-13 武田药品工业株式会社 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003724A1 (en) * 1991-08-26 1993-03-04 The Upjohn Company Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
JP2001510160A (ja) 2001-07-31
BR9810292A (pt) 2000-09-19
AU8449098A (en) 1999-02-10
AR016350A1 (es) 2001-07-04
PE99499A1 (es) 1999-12-18
CA2297133A1 (en) 1999-01-28
PL338140A1 (en) 2000-09-25
AR019724A2 (es) 2002-03-13
KR20010021952A (ko) 2001-03-15
ZA986364B (en) 2000-01-17
AP2000001735A0 (en) 2000-01-16
GB9715298D0 (en) 1997-09-24
BG104062A (en) 2000-11-30
EA200000140A1 (ru) 2000-06-26
HUP0003626A3 (en) 2001-12-28
UY25101A1 (es) 2000-12-29
NO20000230L (no) 2000-01-17
CO4940489A1 (es) 2000-07-24
DZ2563A1 (fr) 2003-02-15
ID23804A (id) 2000-05-11
TR200000133T2 (tr) 2000-09-21
HUP0003626A2 (hu) 2001-05-28
CN1263467A (zh) 2000-08-16
OA11312A (en) 2003-10-24
EP1001784A1 (en) 2000-05-24
SK612000A3 (en) 2000-07-11
WO1999003478A1 (en) 1999-01-28
NO20000230D0 (no) 2000-01-17
MA24608A1 (fr) 1999-04-01

Similar Documents

Publication Publication Date Title
AP9901719A0 (en) Treatment of diabetes with thiazolidinedione and metormin
HK1045111A1 (en) (3-Trihalomethylphenoxy) (4-halophenyl) for the treatment of insulin reisistance and type 2 diabetes
HUP0002053A3 (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
HUP0003876A3 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
PL342517A1 (en) Methods of treating diabetes employing peptidic insulin analoques
IL127219A0 (en) The use of insulin sensitivity enhancers for treatment of hyperuricemia and compositions containing insulin sensitivity enhancers for treating the same
HK1028550A1 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
EG21712A (en) Treatment of insulin resistance
ZA98647B (en) Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
PL343123A1 (en) Treatment of diabetes with rosiglitazone and insulin
IL133907A0 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
IL134045A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL133137A0 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL133138A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
HUP0002668A3 (en) Treatment of diabetes with thiazolidinedione and metformin
EP1207895A4 (en) PEPTIDE AND PEPTIDE ANALOGS FOR THE TREATMENT AND PREVENTION OF DIABETES
HUP0002669A3 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
IL121656A0 (en) Diagnosis prevention and treatment of diabetes